Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Clinical Questions Addressed by the CER (2 of 2)
What is the influence of disease category on effectiveness?
Many assessment instruments are available to evaluate treatment effects, disease progression, health status, and overall well-being of children with JIA. What is the reliability, validity, and responsiveness of these instruments?
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | assessment instrument | reliability | validity | responsiveness
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.